| 摘要 |
Disclosed is a pharmaceutically effective agent and method of use, comprising ancrod which has been incubated with neuraminidase. The neuraminidase-treated ancrod (NTA) can be substituted for ancrod in ancrod therapy, when immunological resistance to the latter has become manifest. Conversely, NTA can be administered initially, and ancrod substituted therefor after NTA resistance becomes manifest. In a second embodiment, the efficacy of ancrod treatment is improved by enterically coated oral administration of native ancrod.
|
